Nplate (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

Amgen today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate(TM) (romiplostim) in the European Union (EU).

The details can be read here.